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Abstract 
Objective 
Antiepileptic drugs (AED) are important for the treatment of epilepsy, psychiatric diseases 
and pain syndromes. Small studies suggested that AED treatment reduces folate and vitamin 
B12 serum levels.  
 
Methods 
This prospective monocenter study aimed at testing the hypothesis that AED treatment is 
associated with folate and vitamin B12 serum levels in a large population. 2730 AED-treated 
and 170 untreated patients with epilepsy and 200 healthy individuals were enrolled.  
 
Results 
Treatment with carbamazepine, gabapentin, oxcarbazepine, phenytoin, primidone or valproate 
was associated with lower mean serum folate levels or with a higher frequency of folate levels 
below the reference range in comparison with all other patients, untreated patients or controls. 
Treatment with phenobarbital, pregabalin, primidone or topiramate was associated with lower 
vitamin B12 levels compared with the entire group of patients. Vitamin B12 serum levels 
were higher in patients treated with valproate compared with the entire group of patients, 
untreated patients and healthy controls. Folate or vitamin B12 levels below the reference 
range were associated with higher mean corpuscular volume (MCV) and higher homocysteine 
plasma levels. Vitamin substitution for three months in 141 patients with folate or vitamin 
B12 levels below the reference range yielded normal vitamin levels in 95% of the 
supplemented patients and reduced MCV and homocysteine plasma levels.   
  
Interpretation 
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Treatment with most of the commonly used AED is associated with reduced folate or vitamin 
B12 serum levels and is a risk factor for hyperhomocysteinemia. Oral substitution is effective 
to restore vitamin, MCV and homocysteine levels.    
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Objective 
Antiepileptic drugs (AED) are frequently used in the treatment of epilepsy, psychiatric 
diseases and pain syndromes. Their side effects include osteoporosis, atherosclerosis, fatigue, 
peripheral neuropathies cerebellar ataxia, neuropsychological impairment and teratogenesis 
including reduced cognitive functions in children of mothers treated with valproate.1-9 Several 
studies have suggested that treatment with distinct AED like valproate, carbamazepine or 
phenytoin is associated with reduced mean serum levels of folate and vitamin B12 and that 
this may mediate AED side effects. As metabolism of homocysteine depends on folate and 
vitamin B12, hyperhomocysteinemia also was observed in associated with AED. However, 
the results of the published studies are conflicting concerning the association of the different 
AED with folate, vitamin B12 or homocysteine plasma levels. In addition, sample sizes were 
small, and data are lacking for most of the newer AED.10-14 Thus, valid and detailed data on 
the association of the commonly used AED with folate and vitamin B12 serum levels are 
missing. 
Suffering from epilepsy is unlikely to directly interfere with serum levels of folate or vitamin 
B12. Thus, patients with epilepsy are a suitable population to investigate the association of 
AED treatment with folate and vitamin B12 serum levels. This prospective monocenter cohort 
study tested the hypothesis that AED treatment is associated with folate and vitamin B12 
serum levels in a population of 2730 AED-treated and 170 untreated patients with epilepsy. 
 
 6
Methods 
Patients 
This prospective study included serial in- and out-patients of the Department for Epileptology 
of the University Hospital Bonn, Germany, who suffered from epilepsy. Period of recruitment 
was January 1st to December 31st 2006. Patients with epilepsy not treated with any AED for at 
least three months were enrolled as disease controls. In Germany, there is no mandatory folate 
supplementation of basic food. The German Robert-Koch-Institut of the Ministry of Health 
recommends (2010) that all women at child bearing age, who do not prevent pregnancy, 
supplement 400 µg folate per day, albeit it states that this is not common practice and that 
only 9% of the German women have a sufficient uptake of naturally occurring folate or 
synthetic folic acid, respectively (www.rki.de). The guidelines of the German Society of 
Neurology recommend supplementation of 5mg folic acid per day for AED-treated women 
with epilepsy who plan to become pregnant. For our study, patients were not eligible if they 
supplemented any vitamin more than once a week, although we recommend such folic acid 
supplementation in respective cases. Otherwise unselected 100 female and 100 male blood 
donors served as second control group. For those healthy controls, no further data were 
available. The study was approved by the local ethics committee. 
 
Clinical protocol and laboratory analyses 
Folate, vitamin B12, hemoglobin, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, total red blood cells, mean corpuscular volume, hematocrit, 
leukocytes, platelets, calcium, potassium, sodium, ammoniac, gamma-glutamyl transferase, 
glutamic oxaloacetic transaminase, glutamate pyruvate transaminase, creatinine, fasting 
homocysteine plasma levels and triglycerides were determined in the clinical routine 
laboratory. Patients with serum folate or vitamin B12 serum levels below the reference range 
were advised to substitute the lacking vitamin. Substitution was per os, 5 mg folic acid or 900 
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µg vitamin B12, respectively. Substituted patients were invited to return after three months. 
Patients who did not follow the invitation to come to our clinic for the management of vitamin 
substitution received written advice for their family doctor.  
 
Fasting plasma total homocysteine concentrations were measured by particle-enhanced 
immunonephelometry with a BN II system (Siemens Healthcare Diagnostics, Eschborn, 
Germany). The reference interval for normal was 4.9-15.0 µmol/l. Fasting serum vitamin B12 
and folate concentrations were measured of a competitive chemiluminescent immunoassay 
with an Access™ immunoassay system (Beckman Coulter, Krefeld, Germany). Reference 
intervals were 3-17 ng/ml for folate and 180–920 pg/ml for vitamin B12.  
 
Statistics 
SPSS version 16 was used for statistical analysis (SPSS, Chicago, IL, USA). Pearson’s Chi2 
tests, t-tests, univariate correlation analysis (Pearson) and univariate analysis of variance 
(ANOVA) were used for univariate analysis of numeric and metric data, respectively. 
Multiple linear regression analysis with a probability for inclusion of 0.05 and of 0.10 for 
exclusion was used to analyze factors of influence on folate and vitamin B12 levels.  
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Results 
Study sample 
2900 serial patients met the inclusion criteria. In patients who presented more than once to the 
clinic during the period of recruitment, the first visit was evaluated. 170 patients were not 
treated with AED, 958 patients were on AED monotherapy, and 1772 patients were treated 
with two or more AED. Intake of AED and personal data are summarized in Supplementary 
table 1. In this rather young study population, age did not correlate with serum folate or 
vitamin B12 levels (not shown). Women had higher serum folate levels (mean ± 1 SD: 6.34 ± 
4.0 ng/ml) than men (5.49 ± 3.30; t = 6.4; p<0.001), whereas vitamin B12 serum levels 
showed no association with gender (not shown).  
 
AED and folate levels 
The 2730 patients treated with AED had significantly more often subnormal serum folate 
levels than the 170 untreated patients and the 200 healthy controls (Table 1). Multivariate 
analysis of AED intake (yes or no, all AED simultaneously, including patients taking more 
than one AED) together with age, gender and vitamin B12 levels as covariables revealed that 
intake of carbamazepine, gabapentin, oxcarbazepine, phenytoin or valproate was associated 
with lower mean folate levels compared with the entire group of patients (Table 2). The 
association of carbamazepine and valproate with lower folate levels was dose-dependent, 
whereas the association of gabapentin, oxcarbazepine and phenytoin was not. Although intake 
of primidone and topiramate was not associated with lower folate levels per se, the daily dose 
of these AED correlated negatively with folate levels. 
Table 3 shows that the mean folate level in patients treated with AED monotherapies was 
6.0±3.5 ng/ml, which did not differ from the healthy controls, but was lower than in untreated 
patients (6.6±3.7 ng/ml). The prevalence of subnormal folate levels was 16% and, thus, higher 
than in controls and untreated patients. Carbamazepine and phenytoin monotherapies were 
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associated with lower mean folate serum levels compared with untreated patients and healthy 
controls, and patients treated with carbamazepine, gabapentin, phenytoin or primidone 
monotherapy had serum folate levels below the reference range more often than untreated 
patients and controls. Correlation analysis of AED dose with folate levels did not reveal 
significant results for patients with monotherapy. 
 
AED and vitamin B12 levels 
The frequency of vitamin B12 levels below the reference range in the entire group of patients 
treated with AED did not significantly differ from untreated patients or controls (Table 1). 
However, treatment with phenobarbital, pregabalin, primidone or topiramate was associated 
with lower mean vitamin B12 levels compared with the entire group of patients (Table 2). The 
association of pregabalin and topiramate with lower mean vitamin B12 levels was dose-
dependent. Although lamotrigine treatment was not associated with mean vitamin B12 serum 
levels or with the prevalence of vitamin B12 levels below the reference range, the daily dose 
of lamotrigine negatively correlated with mean vitamin B12 levels. Surprisingly, valproate 
treatment was dose-dependently associated with higher mean vitamin B12 levels in 
comparison to all other patients.  
In the group of patients treated with AED monotherapies, mean vitamin B12 serum levels and 
the frequency of subnormal vitamin B12 serum levels did not differ from untreated patients or 
controls (Table 3). Concerning the different AED, only the mean vitamin B12 serum levels of 
patients treated with valproate monotherapy were higher than those of untreated patients or 
controls in a dose-dependent manner. Accordingly, the prevalence of subnormal vitamin B12 
serum levels was significantly lower in patients treated with valproate monotherapy than in 
untreated patients and, for trend, in healthy individuals.  
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Subnormal folate or vitamin B12 levels: associated laboratory changes  
We compared routine laboratory parameters of the patients with subnormal folate or vitamin 
B12 serum levels with those of patients with normal folate and vitamin B12 levels. 
Subnormal folate levels were associated with lower vitamin B12, lower red blood cells, 
higher mean corpuscular volume, higher mean corpuscular hemoglobin, higher lymphocyte 
counts, higher platelets, lower calcium, higher gamma-glutamyl transferase and higher 
homocysteine (Supplementary table 2). Subnormal vitamin B12 levels were associated with 
lower folate, lower red blood cells, higher mean corpuscular volume, higher mean corpuscular 
hemoglobin, lower mean corpuscular hemoglobin concentration, higher lymphocytes, higher 
platelets and higher homocysteine (Supplementary table 3). As expected from these data, 
intake of those AED associated with subnormal folate or vitamin B12 serum levels, generally 
was associated with higher homocysteine plasma levels. However, this effect depended on 
folate and vitamin B12 serum levels, which strongly negatively correlated with homocysteine 
plasma levels (the lower folate or vitamin B12, the higher homocysteine). Because of this 
expected dependency, separate analyses for the association of the AED with homocysteine 
plasma levels are not presented in detail. In brief, patients treated with carbamazepine (mean 
homocysteine plasma level ± 1 standard deviation: 16.8±6.1 µmol/L), oxcarbazepine 
(16.1±4.3), phenobarbital (17.5±5.6), phenytoin (19.4±8.5), primidone (16.6±3.6) or 
topiramate (18.9±7.5) had homocysteine plasma levels above the reference range, whereas 
untreated patients (11.9±3.0) and patients treated with clobazam (12.9±2.9), clonazepam 
(13.3±3.0), lamotrigine (13.5±3.9), levetiracetam (11.9±3.2) or valproate (13.5±4.6) had mean 
homocysteine plasma levels within the reference range. Results for pregabalin were 
borderline (15.0±6.4).  
 
 11
Vitamin substitution 
Individuals with subnormal folate or vitamin B12 serum levels were asked to perform vitamin 
substitution under study conditions or to substitute vitamins with the help of their local 
neurologists if they decided not to return to our hospital because of large distances or other 
reasons. A total of 141 patients were substituted at our Department, 109 with folate (5 mg/day 
per os), 16 with vitamin B12 (900 µg/day per os), and 16 with both. Of these patients, 104 
returned after a minimum of three months while still under substitution. Vitamin substitution 
restored normal vitamin levels in 95% of these patients, mean homocysteine plasma levels 
normalized from 16.6±9.3 µmol/l to 11.6±5.7 µmol/l, and MCV decreased from 91.2±5.5 fl to 
89.4±5.9 fl (Supplementary tables 4 and 5). Some patients or their parents reported marked 
improvements of the cognitive performance or seizure frequency after vitamin substitution. 
However, in most of these patients also AED treatment was changed at the presentation in our 
Department. Thus, such speculative clinical effects of vitamin substitution could not be 
monitored validly in the present study.  
 
Interpretation 
In human metabolism, folate is, inter alia, a cofactor for purine- and thymidine synthesis, and 
vitamin B12 is a cofactor in the synthesis of succinyl-CoA from methylmalonyl-CoA. Jointly, 
they act in the remethylation of homocysteine to methionine, a precursor of S-
adenosylmethionine, an ubiquitous methyl group donor. Deficiency of folate or vitamin B12 
can lead to reduced blood cell production, chromosomal instability and disturbed DNA 
methylation, reduced synthesis of catecholamines and myelin as well as 
hyperhomocysteinemia. Thus, subnormal folate or vitamin B12 serum levels are associated 
with anemia, cognitive deficits, vascular disease, osteoporosis, cancer, psychiatric disease, 
spontaneous abortion and congenital malformations. Individuals with subnormal folate or 
vitamin B12 serum levels should be substituted, and women who could become pregnant 
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should prophylactically supplement folate.15 Homocysteine is a neurotoxic excitatory amino 
acid acting at the N-methyl-D-aspartate (NMDA) receptor. Thus, reduced mean folate and 
elevated homocysteine levels associated with AED treatment might promote seizures and 
neuronal damage contributing to the brain atrophy observed in 20-50% of patients with 
epilepsy.16 In addition, elevated homocysteine levels may underlie the increased risk of 
atherosclerosis in epilepsy patients.9  
The present single-center study analyzed a large sample of 2730 unselected AED-treated 
patients with epilepsy (Supplementary table 1). Epilepsy patients treated with AED had more 
often folate serum levels below the reference range than untreated epilepsy patients. Although 
not a proof of causality, this at least argues for AED treatment and against epilepsy as the 
reason for subnormal vitamin levels (Table 1). Admittedly, as a potential source of bias, 
untreated patients will generally have less severe or more recently evolved disease than 
treated patients. Accordingly, Volpe et al. found that children with intractable epilepsy had 
significantly lower intakes of folate and vitamin B12 (among other nutrients) than healthy 
children.20 Thus, it is possible that patients on polytherapy (more likely, intractable epilepsy) 
may differ from the controls in the present study (and the non-treated epilepsy patients as 
well) in terms of dietary vitamin intake. This could have confounded our results, although it 
may not explain the observed AED-specific effects on folate and vitamin B12 serum levels, 
and although most of the patients of our study were adults (Supplementary table 1). A study 
with AED-treated patients due to other indications than epilepsy could help to clarify that 
topic. As possible confounder concerning gender, women had higher folte-levels than men 
arguing that more female than male patients supplemented folic acid or cared for a folate-rich 
nutrition, although regular folic acid supplementation more than two days a week was an 
exclusion criterion.  
Treatment with carbamazepine, gabapentin, oxcarbazepine, phenytoin, primidone or valproate 
was associated with lower mean serum folate levels or was associated with a higher frequency 
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of folate levels below the reference range compared with the entire group of patients or with 
untreated patients and controls (Tables 2 and 3). This association was dose-dependent for 
carbamazepine, primidone and valproate, suggesting that a reduction of these AED may 
restore vitamin levels. Similarly, intake of phenobarbital, pregabalin, primidone or topiramate 
was associated with lower vitamin B12 serum levels, and the association of pregabalin and 
topiramate was dose-dependent (Tables 2 and 3). As the daily dose of of lamotrigine 
negatively correlated with mean vitamin B12 levels, a minor association of lamotrigine with 
vitamin B12 levels cannot be excluded, although the intake of lamotrigine was not per se 
associated with folate or vitamin B12 levels.  
Some of the associations were only observed when the entire sample was analyzed. In the 
subgroup of patients with AED monotherapy, only the associations of carbamazepine, 
gabapentin, phenytoin and primidone with low folate serum levels and the association of 
valproate with higher vitamin B12 serum levels were significant. Therefore, these 
associations may be the most relevant ones. Monotherapies with phenobarbital and other 
AED that were rarely used in our population were not included in this analysis. Thus, 
additional associations of these AED with folate and vitamin B12 levels cannot be excluded, 
as suggested by the analysis of all patients including those with polytherapy. The lack of 
association of lamotrigine, oxcarbazepine, pregabalin, and topiramate monotherapy with 
vitamin B12 levels may be due to the smaller sample size in the monotherapy subgroup 
analysis in combination with rather small effect sizes as indicated by the standardized 
regression coefficient Beta and the ANOVA test value F (Tables 1-3). Accordingly, these 
associations may be of minor relevance.  
In summary, only the intake and daily doses of clobazam, clonazepam and levetiracetam were 
not at all associated with serum folate or vitamin B12 levels in our study population (Tables 2 
and 3). This means that AED with different modes of action and interaction were associated 
with folate or vitamin B12 serum levels. Whereas the strong enzyme inductors carbamazepine 
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and phenytoin were associated with lower folate levels with a relatively high effect size, also 
the enzyme inhibitor valproate was associated with lower mean folate levels, albeit with a 
lower effect size (Table 2). Also gabapentin, which is presumably neither a hepatic enzyme 
inhibitor nor inductor, was associated with lower mean folate serum levels. Thus, mechanisms 
underlying associations of AED with lower folate serum levels may not be restricted to 
hepatic enzyme induction interfering with the folate metabolism. They remain speculative and 
might include interferences with diet, absorption, plasma binding, cellular metabolism and 
renal excretion.  
In our study, serum levels of folate or vitamin B12 were associated with several laboratory 
changes (Supplementary table 2). We did not analyze associations of clinical parameters like 
seizure frequency in association with vitamin levels besides positive anecdotic reports, but the 
clinical relevance of low folate and vitamin B12 serum levels has been evidenced by 
numerous studies. Some of the typical AED side effects are possible symptoms of folate or 
vitamin B12 deficiency, such as fatigue, osteoporosis, atherosclerosis, polyneuropathy, 
neuropsychological impairment or teratogenesis, and hyperhomocysteinemia due to low folate 
or vitamin B12 serum levels may promote seizures.1-7, 9, 17-18  
Treatment with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone or 
topiramate additionally was associated with higher homocysteine plasma levels, treatment 
with pregabalin revealed borderline results. However, these associations were not 
independent, but were explained by the influence of AED on folate and vitamin B12 serum 
levels as major determinants of homocysteine plasma levels. Our observations are in line with 
a smaller study of Belcastro et al.21, who observed hyperhomocysteinemia in association with 
carbamazepine, oxcarbazepine, phenobarbital and topiramate, but not in association with 
lamotrigine and levetiracetam. The association of some AED with hyperhomocysteinemia  
argues that the association of the same AED with folate and vitamin B12 levels is clinically 
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relevant. Interestingly, valproate, associated with lower folate but higher vitamin B12 levels, 
was associated with normal homocysteine levels.  
Vitamin substitution yielded normal vitamin serum levels and decreased homocysteine 
plasma levels and MCV in individuals with subnormal folate or vitamin B12 serum levels 
within approximately three months of substitution (Supplementary table 4). In Germany, 
where the present study was conducted, folate fortification of flour or food is not mandatory, 
although an increasing amount of food is voluntarily fortified. In countries with mandatory 
folate fortification of flour, like USA or Canada, the relevance of AED treatment for folate 
serum levels may be different from countries without fortification.  
In conclusion, the present epidemiological data shows that treatment with any of the 
commonly used AED other than levetiracetam and benzodiazepines, but in particular with 
carbamazepine, gabapentin, phenytoin and primidone, is associated with lower mean serum 
levels of folate or vitamin B12 or, accordingly, with a higher frequency of folate or vitamin 
B12 serum levels below the reference range. Since such conditions are associated with 
clinically adverse conditions, AED treatment requests regular controls of folate and vitamin 
B12 serum levels. Because the method of determination and the reference ranges of folate or 
vitamin B12 have remained controversial,19 prophylactic supplementation may be considered 
as an alternative to regular measurements and selective substitution, especially in women at 
child-bearing age. For restoration of vitamin levels below the reference range, substitution of 
5 mg folate or 900 µg vitamin B12 per os for three months were effective here 
(Supplementary Table 5). As 5 mg folate is the daily dose recommended by the German 
Society of Neurology for AED-treated women with epilepsy (2010), a strict implementation 
of this recommendation is likely to prevent folate deficiency referring to our data. However, 
lower doses like 1 mg/d folate and 15 µg/d vitamin B12 per os are eventually more suited for 
continuation and for prophylactic substitution. This has to be defined in prospective studies. 
The dose-dependency of the association of intake of some AED with folate and vitamin B12 
 16
serum levels suggests that reductions of AED dose, if possible, may also reduce side effects 
mediated by reduced folate or vitamin B12 levels. Studies are needed to further proof 
causality of AED treatment with associated laboratory changes like increased MCV or 
homocysteine plasma levels mediated by reduced folate and vitamin B12 levels, and studies 
are needed to examine the full clinical implications of these potential AED side effects.  
 17
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Table 1: Folate and vitamin B12 serum levels in the study population 
 Folate Vitamin B12 
 
Mean serum 
levels (ng/ml) 
± SD 
Frequency of 
subnormal 
serum levels 
Versus 
untreated 
patients 
Versus 
healthy 
controls 
Mean serum 
levels (pg/ml) 
± SD 
Frequency of 
subnormal 
serum levels 
Versus 
untreated 
patients  
Versus 
healthy 
controls 
AED-treated patients  
(n=2730) 
5.8±3.7 0.17 
13.7; 
<0.001 
16.3; 
<0.001 
381±184 0.06 
0.17; 
0.685 
0.19; 
0.661 
Untreated patients   
(n=170) 
6.6±3.7 0.06  
0.01; 
0.950 
366±187 0.07  
0.71; 
0.400 
Healthy controls  
(n=200) 
6.3±3.7 0.06 
0.85; 
0.357 
 366±160 0.05 
0.71; 
0.400 
 
 
The frequencies of subnormal serum folate or vitamin B12 levels in AED-treated patients, untreated patients and healthy controls were compared by 
Pearson’s Chi2 analysis (Chi2; p). SD = standard deviation. For SI units, folate (ng/ml) must be multiplied with 2.27 (=nmol/l), vitamin B12 (pg/ml) 
with 0.74 (=pmol/l). 
Table 2: AED and vitamins in all patients: linear regression analysis  
 Folate Vitamin B12 
AED  
(yes/no) 
Mean serum levels 
(ng/ml) ± SD 
AED intake and 
serum levels  
(Beta; p)1 
AED dose and 
serum levels  
(Beta; p)2 
Mean serum levels 
(pg/ml) ± SD 
AED intake and 
serum levels  
(Beta; p)1 
AED dose and 
serum levels  
(Beta; p)2 
All patients (n=2900) 5.9±3.7   380±184   
Clobazam (n=229) 5.6±4.0 -0.018; 0.312 0.001; 0.998 382±181 0.023; 0.193 -0.047; 0.480 
Clonazepam (n=44) 6.3±5.3 0.010; 0.582 0.292; 0.069 405±270 0.010; 0.572 -0.037; 0.819 
Carbamazepine (n=721) 4.9±3.1 -0.160; <0.001 -0.094; 0.014 342±146 -0.030; 0.124 0.021; 0.570 
Gabapentin (n=128) 5.9±3.7 -0.038; 0.033 0.081; 0.366 359±148 -0.004; 0.821 -0.-022; 0.803 
Lamotrigine (n=1001) 6.3±3.9 0.034; 0.076 -0.051; 0.091 378±175 0.001; 0.946 -0.069; 0.023 
Levetiracetame (n=1062) 5.8±3.7 -0.012; 0.493 -0.018; 0.564 376±185 0.017; 0.336 -0.047; 0.180 
Oxcarbazepine (n=390) 5.8±3.6 -0.039; 0.042 -0.090; 0.079 365±180 0.001; 0.997 -0.063; 0.222 
Phenobarbital (n=193) 5.3±3.7 -0.030; 0.091 -0.080; 0.273 358±156 -0.045; 0.010 -0.054; 0.463 
Phenytoin (n=157) 4.5±2.8 -0.099; <0.001 -0.118; 0.132 373±202 0.023; 0.199 0.140; 0.085 
Pregabalin (n=231) 5.3±3.8 -0.028; 0.118 -0.061; 0.366 344±186 -0.040; 0.025 -0.153; 0.025 
Primidone (n=103) 5.4±4.4 -0.024; 0.174 -0.311; 0.002 354±158 -0.035; 0.047 -0.006; 0.950 
Topiramate (n=351) 5.6±4.2 -0.012; 0.492 -0.113; 0.033 341±168 -0.069; <0.001 -0.155; 0.004 
Valproate (n=645) 6.3±3.6 -0.045; 0.026 -0.101; 0.011 496±316 0.324; <0.001 0.084; 0.037 
Only AED that were taken by at least 1% (n=29) of the patients were included. The overall significance for folate was F=12.35; p<0.001 and 
F=28.69; p<0.001 for vitamin B12.  
1 The standardized coefficient Beta and p are given for linear regression analysis. All AED were analyzed simultaneously with age and gender as 
additional covariables.  
2 Linear regression: The standardized coefficient Beta and p are given for AED dose with age and gender as covariables in addition to folate, when 
vitamin B12 was the independent variable and vice versa. 
 
Table 3: AED and vitamins in patients with monotherapy: linear regression analysis 
 Folate Vitamin B12 
 
 
Mean serum levels2 
Frequency of subnormal 
serum levels3 
Mean serum levels2 
Frequency of subnormal 
serum levels3 
AED 
(ng/ml) 
± SD 
Versus 
no 
AED 
Versus 
controls 
AED 
dose 
 
Versus 
no 
AED 
Versus 
controls 
(pg/µl)  
± SD 
Versus 
no AED 
Versus 
controls 
AED 
dose 
 
Versus 
no 
AED 
Versus 
controls 
All patients  
(n=9581) 
6.0±3.5
4.06; 
0.044 
1.07; 
0.302 
 0.16 
6.55; 
0.011 
16.3; 
<0.001 
389±190
2.36; 
0.125 
1.09; 
0.297 
 0.06 
0.237; 
0.627 
0.247; 
0.380 
Carbamazepine 
(n=215) 
5.1±3.0
18.6; 
<0.001 
12.83; 
<0.001 
-0.099; 
0.144 
0.24 
22.3; 
<0.001 
17.9; 
<0.001 
339±143
3.28; 
0.071 
2.08; 
0.150 
-0.060; 
0.381 
0.09 
0.64; 
0.455 
0.450; 
0.535 
Gabapentin 
(n=26) 
6.0±3.6
0.557; 
0.456 
0.134; 
0.715 
0.325; 
0.122 
0.16 
4.57; 
0.039 
3.94; 
0.047 
355±193
0.103; 
0.749 
0.044; 
0.834 
-0.151; 
0.273 
0.04 
0.28; 
0.897 
0.066; 
0.797 
Lamotrigine 
(n=293) 
7.0±4.0
0.953; 
0.329 
3.55; 
0.060 
0.089; 
0.448 
0.05 
0.12; 
0.832 
0.23; 
0.881 
347±148
1.84; 
0.176 
1.07; 
0.301 
-0.004; 
0.973 
0.08 
0.16; 
0.851 
1.254; 
0.263 
Levetiracetame 6.4±3.8 0.115; 0.063; 0.043; 0.10 1.44; 1.95; 404±235 2.15; 1.93; 0.044; 0.04 0.366; 0.030; 
(n=67) 0.735 0.801 0.731 0.266 0.162 0.143 0.166 0.736 0.762 0.863 
Oxcarbazepine 
(n=96) 
6.1±3.3
1.08; 
0.300 
0.143; 
0.706 
-0.084; 
0.419 
0.11 
2.53; 
0.155 
3.35; 
0.095 
379±187
0.377; 
0.540 
0.430; 
0.513 
0.055; 
0.593 
0.07 
0.053; 
0.805 
0.629; 
0.293 
Phenytoin 
(n=15) 
4.0±1.6
6.92; 
0.009 
5.42; 
0.021 
0.160; 
0.599 
0.27 
8.36; 
0.018 
9.633; 
0.013 
412±338
0.944; 
0.332 
0.808; 
0.370 
0.232; 
0.385 
0.07 
0.00; 
0.988 
0.080; 
0.778 
Primidone 
(n=10) 
5.4±5.3
1.036; 
0.310 
0.61; 
0.436 
-0.431; 
0.208 
0.40 
15.1; 
0.004 
17.1; 
0.003 
292±145
2.07; 
0.151 
1.43; 
0.233 
0.295; 
0.128 
0.20 
2.52; 
0.159 
3.98; 
0.104 
Topiramate 
(n=26) 
6.4±4.7
0.075; 
0.785 
0.010; 
0.921 
-0.073; 
0.689 
0.16 
3.27; 
0.089 
3.94; 
0.070 
304±84 
3.69; 
0.056 
2.51; 
0.115 
0.233; 
0.214 
0.12 
0.962; 
0.399 
2.00; 
0.164 
Valproate 
(n=176) 
6.5±3.6
0.025; 
0.876 
0.422; 
0.516 
-0.102; 
0.179 
0.08 
0.531; 
0.529 
0.909; 
0.408 
487±197
43.4; 
<0.001 
36.0; 
<0.001 
0.153; 
0.044 
0.02 
5.12; 
0.029 
3.01; 
0.096 
No AED 
(n=170) 
6.6±3.7  
0.627, 
0.429 
 0.06  
0.035; 
0.885 
364±186
0.023; 
0.880 
  0.06  
0.406; 
0.653 
Healthy 
controls 
(n=200) 
6.3±3.7
0.627, 
0.429 
  0.06 
0.035; 
0.885 
 366±160  
0.023; 
0.880 
 0.05 
0.406; 
0.653 
 
 1Since monotherapies with patient numbers <10 were not analyzed (n=34 patients), the sum of the patient numbers shown in the table is 924. 
2The mean serum folate or vitamin B12 levels of patients treated with AED monotherapy were compared with those of the patients who were not 
treated with AED or with controls, respectively, by ANOVA (F; p). “AED dose”: Linear regression analysis (Beta; p) with AED doses, age, gender 
and the serum level of the vitamin other than the independent variable as covariables and folate or vitamin B12 serum levels as independent 
variable.  
3The frequency of subnormal folate or vitamin B12 serum levels in patients treated with the respective AED in monotherapy was compared with the 
frequency in untreated patients (“no AED”) or controls by Pearson’s Chi2 test (Chi2; p).  
 
 
Supplementary table 1: Patients and treatment 
 
 
All patients Patients with monotherapy 
AED 
n 
(ratio) 
Daily dose (mg) 
± SD (range) 
Age (years) ± SD  
(range) 
Female 
gender 
n 
(ratio) 
Daily dose (mg) 
± SD (range) 
Age (years) ± SD  
(range) 
Female 
gender 
All patients 2900  
38.2±14.7 
(3-85) 
0.50 
 
958 
(1.00) 
 
36.8±15.7 
(3-85) 
0.53 
Clobazam 
229  
(0.08) 
15.2±9.3 
(3-60) 
38.7±13.2 
(8-80) 
0.55 
5 
(<0.01) 
16.0±9.2 
(5-50) 
44.6±13.4 
(31-67) 
0.80 
Clonazepam 
44 
(0.02) 
2.1±1.7 
(1-8) 
43.7±15.0 
(15-78) 
0.68 
3 
(<0.01) 
1.3±0.8 
(0.5-2) 
45.7±26.6 
(15-63) 
0.67 
Carbamazepine 
721 
(0.25) 
1067±463 
(100-2800) 
41.1±13.4 
(9-80) 
0.48 
215 
(0.22) 
934±443 
(100-2700) 
14.0±13.4 
(9-75) 
0.51 
Diazepam 
26 
(<0.01) 
11.5±8.1 
(3-30) 
39.6±8.9 
(25-54) 
0.42 
1 
(<0.01) 
10 43 0.00 
Ethosuximid 21 783±331 28.8±13.0 0.48 1 775 7 1.00 
(<0.01) (250-1500) (7-56) (<0.01) 
Felbamat 
16 
(<0.01) 
2481±1027 
(800-3600) 
32.1±11.4 
(16-54) 
0.25 
1 
(<0.01) 
3600 54 0.00 
Gabapentin 
128 
(0.04) 
2049±1016 
(800-3600) 
45.6±16.0 
(15-83) 
0.51 
26 
(0.03) 
1827±883 
(600-4800) 
52.7±15.7 0.50 
Lamotrigine 
1001 
(0.35) 
385±239 
(12.5-1500) 
37.3±13.9 
(3-85) 
0.51 
293 
(0.31) 
300±163 
(12.5-850) 
34.7±15.6 0.59 
Levetiracetam 
1062 
(0.37) 
2539±997 
(25-7000) 
39.5±13.8 
(12-78) 
0.48 
67 
(0.07) 
2183±837 
(500-4000) 
40.8±15.8 
(12-74) 
0.51 
Lorazepam 
12 
(<0.01) 
2.0±1.1 
(1-5) 
35.3±13.8 
(13-56) 
0.42 
0 
 
   
Mesuximid 
3 
(<0.01) 
650±433 
(150-900) 
23.7+7.6 
(17-32) 
0.33 
0 
 
   
Oxcarbazepine 
390 
(0.13) 
1401±620 
(150-3600) 
35.9±14.3 
(4-78) 
0.48 
96 
(0.10) 
1079±541 
(150-3000) 
35.7±15.7 
(8-78) 
0.50 
Phenobarbital 193 123±73 41.3±12.3 0.44 7 193±84 43.0±4.9 0.86 
(0.07) (15-450) (13-72) (<0.01) (100-300) (36-49) 
Phenytoin 
157 
(0.05) 
300±108 
(50-600) 
41.4±14.2 
(13-79) 
0.40 
15 
(0.02) 
318±103 
(100-500) 
48.0±16.4 
(24-79) 
0.33 
Potassium-
bromide 
4 
(<0.01) 
1806±1117 
(850-3400) 
28.5±9.5 
(18-38) 
0.75 0    
Pregabalin 
231 
(0.08) 
328±154 
(50-900) 
38.8±12.5 
(14-73) 
0.44 
3 
(<0.01) 
200±87 
(150-300) 
52.0±18.0 
(35-71) 
1.00 
Primidone 
103 
(0.04) 
579±316 
(60-1750) 
42.7±14.1 
(16-76) 
0.49 
10 
(0.01) 
656±276 
(250-1125) 
43.9±17.9 
(23-73) 
0.70 
Sultiam 
24 
(<0.01) 
243±167 
(50-600) 
18.5±11.5 
(5-46) 
0.58 
13 
(0.01) 
215±424 
(50-450) 
12.7±4.9 
(6-23) 
0.62 
Tiagabin 
11 
(<0.01) 
59±81 
(15-300) 
40.7±10.3 
(22-55) 
0.36 0    
Topiramate 
351 
(0.12) 
299±178 
(20-1000) 
35.7±13.0 
(4-76) 
0.51 
26 
(0.03) 
213±164 
(25-800) 
36.9±15.5 
(12-76) 
0.65 
Valproate 645 1545±780 36.0±14.2 0.44 176 1290±631 32.5±14.8 0.45 
(0.22) (40-5400) (4-80) (0.18) (40-4500) (7-80) 
Vigabatrin 
17 
(<0.01) 
1897±1067 
(500-4000) 
35.3±14.3 
(8-55) 
0.53 0    
Zonesamid 
5 
(<0.01) 
215±122 
(75-400) 
30.2±15.9 
(18-55) 
0.40 0    
No AED 
170 
(0.06) 
 
39.2±15.8 
(16-83) 
0.53     
Controls 200 
 
 
 0.50     
  
The daily dose is defined as the total intake of the respective AED per day. “Female gender” shows the ratio of women.  
Supplementary table 2: Association of subnormal folate serum levels with further 
laboratory abnormalities 
 Subnormal folate 
levels (n=478) 
Normal folate 
levels (n=2422) 
ANOVA1 
Vitamin B12 (pg/ml) 325±176 390±182 51.2; <0.001 
Red blood cells (*106/µl) 4.61±0.48 4.66±0.45 4.56; 0.033 
Mean corpuscular volume (fl) 91.1±5.6 89.9±5.1  19.8; <0.001 
Mean corpuscular hemoglobin (pg) 31.0±2.2 30.6±2.0 17.3; <0.001 
Lymphocytes (*103/µl) 6.62±2.54 6.32±1.92 7.42; 0.006 
Platelets (*103/µl) 267±73 256±68 10.6; 0.001 
Calcium (mmol/l) 2.26±0.11 2.31±0.11 14.2; <0.001 
Gamma-glutamyl transferase (U/l) 85.9±87.3 57.6±66.0 38.2; <0.001 
Homocysteine (µmol/l) 17.7±10.3 12.3±5.2 19.9; <0.001 
 
1F; p 
 
 
 
 
Supplementary table 3: Association of subnormal vitamin B12 serum levels with further 
laboratory abnormalities 
 Subnormal 
vitamin B12 levels 
(n=170) 
Normal vitamin 
B12  levels 
(n=2730) 
ANOVA1 
Folate (ng/ml) 4.32±3.0 6.00±3.7 34.6; 0.001 
Red blood cells (*106/µl) 4.55±0.46 4.65±0.46 7.78; 0.005 
Mean corpuscular volume (fl) 91.6±6.0 90.0±5.2 14.2; 0.001 
Mean corpuscular hemoglobin (pg) 31.1±2.3 30.6±2.0 6.67; 0.010 
Mean corpuscular h. c. (g/dl)2 33.8±1.1 34.1±1.1 6.91; 0.009 
Lymphocytes (*103/µl) 6.71±2.4 6.35±2.0 4.15; 0.042 
Platelets (*103/µl) 279±71 257±69 16.2; 0.001 
Homocysteine (µmol/l) 17.8±11.9 14.3±7.3 5.63; <0.001 
1F; p 
2 Mean corpuscular hemoglobin concentration. 
 
 
Supplementary table 4: Vitamin substitution  
 
Substituted due to 
subnormal levels 
Follow-up after 3 
months 
Subnormal levels 
after 3 months 
folate  n=125 n=94 n=53 
vitamin B12 n=32 n=20 n=0 
total n=1411 n=1042 n=5 
 
116 patients were substituted with both folate and vitamin B12. 
2At follow-up, 10 patients were substituted with both folate and vitamin B12. 
3After 3 months of substitution, 60% of patients treated with folate had folate serum levels 
higher than the top of the measurement range, i.e. 25 ng/ml. The 5 patients who presented 
with persistingly low levels all had serum folate levels below 2 ng/ml, thus, compliance 
seemed questionable. 
 Supplementary table 5: Laboratory changes after vitamin substitution  
Parameter 
Before 
substitution 
After 
substitution4 
t-test 
(t;p) 
Folate (ng/ml)1 2.22±0.49 20.2±8.1 21.5; <0.001 
Vitamin B12 (pg/ml)2 154±15.7 434±213 6.25; <0.001 
Homocysteine (µmol/l)3 16.6±9.3 11.6±5.7 7.52; <0.001 
Mean corpuscular volume (fl)3 91.2±5.5 89.4±5.9 3.70; <0.001 
 
Mean absolute levels ± SD of laboratory parameters in patients with subnormal folate (n=125) 
or subnormal vitamin B12 plasma levels (n=32) before and after substitution as compared 
with the t-test.  
After substitution, there were no significant changes on the parameters hemoglobin, mean 
corpuscular hemoglobin, mean corpuscular hemoglobin concentration, total red blood cells, 
hematocrit, leukocyte counts, platelet counts, calcium, potassium, sodium, ammoniac, 
gamma-glutamyl transferase, glutamic oxaloacetic transaminase, glutamate pyruvate 
transaminase, creatinine, and triglycerides. 
1Patients substituted with folate only (n=125).  
2Patients substituted with vitamin B12 only (n=32). 
3All patients substituted with folate or vitamin B12 or both (n=141).  
4After substitution, 60% of the patients had folate serum levels higher than the top of the 
measurement range, i.e., 25 ng/ml. Due to this technical limitation, the effective folate serum 
levels after substitution were supposedly higher than shown in this table. 
